| 18.94 -0.17 (-0.89%) | 05-13 13:09 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.14 | 1-year : | 25.25 |
| Resists | First : | 19.81 | Second : | 21.62 |
| Pivot price | 19.44 |
|||
| Supports | First : | 16.88 | Second : | 14.05 |
| MAs | MA(5) : | 19.49 |
MA(20) : | 19.59 |
| MA(100) : | 18.79 |
MA(250) : | 12.29 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 30.1 |
D(3) : | 35.6 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 25.77 | Low : | 3.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GLUE ] has closed above bottom band by 24.0%. Bollinger Bands are 60.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.05 - 20.14 | 20.14 - 20.24 |
| Low: | 18.72 - 18.84 | 18.84 - 18.96 |
| Close: | 18.89 - 19.08 | 19.08 - 19.26 |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Mon, 11 May 2026
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Sat, 09 May 2026
Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Sat, 09 May 2026
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Strong Recent Share Price Momentum - simplywall.st
Thu, 07 May 2026
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Investing News Network
Thu, 07 May 2026
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 07 May 2026
MONTE ROSA THERAPEUTICS ($GLUE) Releases Q1 2026 Earnings - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 5.721e+007 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 10,960 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.585e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -31.3 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 787.6 % |
| Return on Equity (ttm) | -7.7 % |
| Qtrly Rev. Growth | 1.2367e+008 % |
| Gross Profit (p.s.) | -58.18 |
| Sales Per Share | -10.33 |
| EBITDA (p.s.) | -6.11585e+006 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.84 |
| Price to Cash Flow | 8.71 |
| Dividend | 0 |
| Forward Dividend | 1.584e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|